Interview with Zheng Hong, Chairman, China Pharmaceutical Industry Association…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company…
Address: No. 20, Zhichun Rd., Haidian District, Beijing,China
Tel: -82080673
China Pharmaceutical Industry Association (CPIA) was founded in September 1988 and it is a non-governmental, non-profit association, Its members are mainly from large and medium sized pharmaceutical corporations, pharmaceutical machinery and medicinal glass packaging companies, regional pharmaceutical industrial associations, pharmaceutical research institutions, designing institutes, universities, colleges and secondary schools of this sector etc. CPIA is a national level society registered in the Ministry of Civil Affairs. The State-owned Assets Supervision and Administration Commission of the State Council directly administer the association. CPIA is a member and also a standing council director’s unit of China Federation of Industrial Economics.
Now CPIA has 338 members, the industrial output value of which (added together) is nearly up to 80 percent of that of the whole China’s pharmaceutical industry. CPIA also has 15 professional working units: 2 branch associations, 13 working & coordinating committees and communication groups.
Industry association
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…